| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aea57db10fe6e572d4a54808447081e9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2030-8831
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B10-0058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2010-0061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B10-007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B10-0051 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/H01J49-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-336 |
| filingDate |
2010-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f4eeca1dfbc1b60572d099febf6c5b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c49163639ea9faa82d7352448c5c1ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17bdf0559a425282e77af6af2aaf6228
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_400bafb67609782ce7a43b609e30031d |
| publicationDate |
2011-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011172271-A1 |
| titleOfInvention |
Urinary Triaosylceramide (GB3) as a Marker of Cardiac Disease |
| abstract |
The present invention describes a method for determination of urinary globotriaosylceramide (Gb3) levels in non-Fabry disease cardiac patients. Determination of Gb3 levels provides a screening method for determining cardiac risk and may offer an alternative therapeutic option for cardiac disease management or cardiac disease risk mitigation by lowering Gb3 levels by the use of pharmacological chaperones or other agents. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012154681-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014012043-A1 |
| priorityDate |
2009-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |